EDU 35 - Biological Insights into Selection of Specific HPV+ Oropharyngeal Cancer Patients Appropriate for Radiation Dose De-escalation
MODERATOR(S)
Pippa Cosper, MD, PhD - University of Wisconsin
session DESCRIPTION
It is known that human papilloma virus (HPV) induced oropharyngeal cancers are more radiosensitive than HPV-negative cancers, however de-escalation trials based on HPV status alone have proven unsuccessful. It is clear that biomarkers other than p16 are necessary for appropriate patient radiation dose de-escalation selection. In this session, we aim to discuss multiple biological factors including the aerobic state of the tumor tissue, immune infiltration and HPV cfDNA kinetics that may serve as additional biological biomarkers indicative of patient selection for radiation dose de-escalation. The goal is to increase collaborative trials with biologic correlative endpoints that could move the needle for HPV+ head and neck cancer patients.
learning objectives
- Identify multiple biological parameters that may distinguish HPV+ oropharyngeal cancer patients eligible for radiation dose de-escalation.
- Determine how cell-free HPV DNA can predict tumor burden and treatment response.
Credits
| AMA PRA Category 1 Credits: | 1.00 |
Presentations
-
05:00pm - 05:02pm ETSpeaker: Pippa Cosper, MD, PhD - University of Wisconsin, Madison
-
05:02pm - 05:17pm ETSpeaker: Nadeem Riaz, MD, MS - memorial sloan kettering, new york
-
05:17pm - 05:32pm ET
Insights into the TME in HPV+ Oropharyngeal Cancers that May Allow for Radiation Dose De-escalation in the Post-operative Setting
Speaker: David Routman, MD - Mayo Clinic Rochester, Rochester -
05:32pm - 05:47pm ET
Cell-free HPV DNA (cfDNA) Levels and Kinetics to Predict Patients Appropriate for Radiation Dose De-escalation.
Speaker: Daniel Faden, MD - Mass General Brigham, Harvard Medical School, Boston -
05:47pm - 06:00pm ETSpeaker: Pippa Cosper, MD, PhD - University of Wisconsin, Madison